WEBULL
News
CINGW
0.0385
0.00%
0.00
Weekly Report: what happened at CINGW last week (1124-1128)?
Weekly Report · 4d ago
Weekly Report: what happened at CINGW last week (1117-1121)?
Weekly Report · 11/24 09:19
Cingulate Inc. Signs Exclusive Commercial Supply Agreement with Bend Bio Sciences
Reuters · 11/18 21:28
Weekly Report: what happened at CINGW last week (1110-1114)?
Weekly Report · 11/17 09:19
Biopharma firm Cingulate's Q3 net loss widens, misses analyst expectations
Reuters · 11/13 13:09
Cingulate Inc. posts third quarter loss of $6.0 million
Reuters · 11/13 13:00
CINGULATE Q3 NET INCOME USD -7.3 MILLION VS. IBES ESTIMATE USD -3.82 MILLION
Reuters · 11/13 13:00
Cingulate Inc. Files Initial Statement of Beneficial Ownership for Chief Commercial Officer Bryan Wade Downey
Reuters · 11/10 23:00
Cingulate Inc. Appoints Bryan Downey as Chief Commercial Officer
Reuters · 11/10 13:03
Weekly Report: what happened at CINGW last week (1103-1107)?
Weekly Report · 11/10 09:19
Weekly Report: what happened at CINGW last week (1027-1031)?
Weekly Report · 11/03 09:18
CINGULATE PRESENTS POSITIVE PHASE 3 RESULTS FOR CTX-1301 DEMONSTRATING STATISTICALLY SIGNIFICANT EFFICACY AND ENTIRE ACTIVE-DAY SYMPTOM CONTROL
Reuters · 10/28 12:00
Weekly Report: what happened at CINGW last week (1020-1024)?
Weekly Report · 10/27 09:20
Cingulate’s Lead ADHD Candidate CTx-1301 Selected for Podium Presentation at AACAP Annual Meeting
Barchart · 10/23 15:45
Weekly Report: what happened at CINGW last week (1013-1017)?
Weekly Report · 10/20 09:19
FDA ACCEPTS CINGULATE’S NEW DRUG APPLICATION FOR CTX-1301 IN ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) AND SETS A MAY 31, 2026 PDUFA DATE
Reuters · 10/14 12:00
Weekly Report: what happened at CINGW last week (1006-1010)?
Weekly Report · 10/13 09:19
Weekly Report: what happened at CINGW last week (0929-1003)?
Weekly Report · 10/06 09:19
Weekly Report: what happened at CINGW last week (0922-0926)?
Weekly Report · 09/29 09:20
Cingulate Inc. Held Special Meeting of Stockholders
Reuters · 09/25 21:01
More
Webull provides a variety of real-time CINGW stock news. You can receive the latest news about Cingulate through multiple platforms. This information may help you make smarter investment decisions.
About CINGW
Cingulate Inc. is a biopharmaceutical company. The Company is focused on the development, manufacturing, and commercialization of pharmaceutical products that utilize its precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles. It focuses on the treatment of attention deficit/hyperactivity disorder (ADHD). The Company is in the development of two lead product candidates, such as CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). The Company’s CTx-1301 and CTx-1302 are being developed for the treatment of ADHD in the three core patient segments: children (ages 6-12), adolescents (ages 13-17), and adults (ages18+). In addition, the Company has a third product to treat anxiety, CTx-2103, in a formulation stage. Its CTx-1301, CTx-1302 and CTx-2103 drug candidates contain three releases of active pharmaceutical ingredient combined into one small tablet dosage form.